Hepatitis C treatment for patients post liver transplant

Current Opinion in Organ Transplantation

Volumn 20, Issue 3, 2015, Pages 251-258

  Mariño, Zoe ^a   Londoño, Maria Carlota ^a   Forns, Xavier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Direct acting antivirals; Hepatitis C recurrence; Interferon free combinations; Liver function; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HUMAN; LIVER FUNCTION; LIVER GRAFT; LIVER TRANSPLANTATION; NONHUMAN; POSTOPERATIVE PERIOD; PREEMPTIVE THERAPY; PRIORITY JOURNAL; REVIEW; THERAPY DELAY; VIRAL CLEARANCE; LIVER FUNCTION TEST; PATHOPHYSIOLOGY;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION;

EID: 84973559197     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000197     Document Type: Review

References (36)

1. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680–687.
2. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852–858.
3. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41:830–836.
4. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132:1746–1756.
5. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142:1373–1383; e1371.
6. Charlton M. Preemptive treatment of recurrent hepatitis C infection. Liver Transpl 2002; 8:S50–S54.
7. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17:528–538.
8. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41:289–298.
9. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5:118–124.
10. Gurusamy KS, Tsochatzis E, Toon CD, et al. Antiviral prophylaxis for the & prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2014; 12:CD006573.
11. Complete and updated review supporting the nonbeneficial effect of IFN-based therapies in early phases after liver transplantation.
12. Donato MF, Monico S, Malinverno F, et al. Bridging all oral DAA therapy from wait time to postliver transplant to improve HCV eradication? Liver Int 2014; 35:1–4.
13. Londoño MC, Crespo G, Forns X. Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. Curr Opin Organ Transplant 2013; 18:271–278.
14. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11:1051–1057.
15. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53:317–324.
16. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49:274–287.
17. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6:1586–1599.
18. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15:699–709.
19. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2013; 60:78–86.
20. Burton JR Jr, O’Leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; 61:508–514.
21. Faisal N, Yoshida EM, Bilodeau M, et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014; 13:525–532.
22. Forns X, Samuel D, Mutimer D. Interim SVR12 results from the Telaprevir phase 3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection. J Hepatol 2014; 60 (Suppl 1):S481.
23. Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with && decompensated cirrhosis, pre and posttransplantation. J Hepatol 2014; 61:S120–S131. Extensive and detailed review of IFN-free antiviral therapies performed in decompensated patients. The article updates the peculiarities of this population in terms of efficacy and safety.
24. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of & compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2014; 148:108–117. Report from the first IFN-free combination administered in liver transplant recipients. Sofosbuvir plus ribavirine showed good efficacy results in a difficult-to-treat population with 40% cirrhotic patients and 88% of previous nonresponders after liver transplantation. Most importantly, it showed an outstanding improvement in safety profile when compared with previous standard therapies to date.
25. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program && for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2015; DOI:10.1002/hep.27681. [Epub ahead of print] First reported compassionate use program evaluating sofosbuvir-based therapies in severe HCV recurrences. Sustained virological response was shown to be significantly higher in early cholestatic recurrences than in posttransplant cirrhotic patients. Viral eradication was associated with a relevant improvement or stabilization of liver function and clinical status in the majority of patients.
26. Pungpapong S, Werner KT, Aqel B, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation. Hepatology 2014; 60 (Suppl S1):201A.
27. Reddy KR, Everson G, Flamm S, et al. Ledipasvir/sofosbuvir with ribavirin for the && treatment of HCD in patients with posttransplant recurrence: preliminary results of a prospective multicenter study. Hepatology 2014; 60 (Suppl S1):200A. Preliminary report from the first trial evaluating sofosbuvir and ledipasvir in a large postliver cohort of HCV-infected patients, presented in the last International Meeting. Liver function was shown to significantly impact response rates.
28. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for & HCV after liver transplantation. N Engl J Med 2014; 371:2375–2382. Results from the phase 2 trial evaluating a three-direct antiviral drug combination of ombitasvir/paritaprevir/ritonavir, dasabuvir, and ribavirine in a small cohort of transplanted HCV patients with mild disease. Drug–drug interactions with immunosupressive therapy were easily managed and no toxicity or rejection was reported.
29. Leroy V, Dumortier J, Coilly A, et al. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: The ANRS CO23 CUPILT study. Hepatology 2014; 60 (Suppl S1):207A.
30. Mariño Z, van Bommel F, Forns X, Berg T. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut 2013; 63:207–215.
31. Olysio product information. http://ec.europa.eu/health/documents/community-register/2014/20140514128513/anx_128513_en.pdf. Accessed 15 April 2015.
32. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50:719–728.
33. Londoño MC, Perello C, Cabezas J, et al. The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. J Hepatol 2015; 62:311–316.
34. Brown RS, Reddy KR, O’Leary JG, et al. Safety and efficacy of new DAA- & based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational Study. Hepatology 2014; 60 (Suppl S1):1269A. Preliminary real-life experience of the use of sofosbuvir and simeprevir in a large cohort of HCV-infected patients after liver transplantation, presented in the last International meeting.
35. Londoño MC, Herzer K, Moreno C, et al. Safety and efficacy of Simeprevir in combination with Daclatasvir or Sofosbuvir in patients with severe hepatitis C recurrence after liver transplantation: results from compassionate use in Europe. Hepatology 2014; 60 (Suppl S1):1287A.
36. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for posttransplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46:923–927.